


Elubrixin

Cat. No.:	HY-18263A
CAS No.:	688763-64-6
Molecular Formula:	C ₁₇ H ₁₇ Cl ₂ FN ₄ O ₄ S
Molecular Weight:	463.31
Target:	CXCR; Interleukin Related
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC ₅₀ of 260.7 nM) and shape change (IC ₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^{[1][2][3]} .	
IC₅₀ & Target	CXCR2	IL-8
In Vitro	Elubrixin has an inhibitory effect on neutrophils in a dose-dependent fashion ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. *Expert Opin Investig Drugs*. 2015;24(7):949-56.
- [2]. Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. *Br J Clin Pharmacol*. 2011 Aug;72(2):282-93.
- [3]. Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. *Pulm Pharmacol Ther*. 2007;20(1):52-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA